Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 2/20 | 0.56 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.46 |
| ▸ | RHEB | Q15382 | 9/20 | 0.43 |
| ▸ | HTR6 | P50406 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.41 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.41 |
| ▸ | ITGAL | P20701 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | ADK | P55263 | 1/20 | 0.41 |
| ▸ | ASH1L | Q9NR48 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
| ▸ | HTR1B | P28222 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20540332 | 0.75 | PIK3CD (0.64) | AHRPIK3CDRHEBHTR6MAPK1 | |
| SCHEMBL879761 | 0.73 | AHR (0.58) | AHRPIK3CDRHEBHTR6MAPK1 | |
| SCHEMBL3335002 | 0.73 | AHR (0.58) | AHRPIK3CDRHEBHTR6MAPK1 | |
| SCHEMBL30681623 | 0.73 | AHR (0.57) | AHRPIK3CDRHEBMAPK1ADRB1 | |
| SCHEMBL65514 | 0.71 | AHR (0.56) | AHRPIK3CDRHEBHTR6MAPK1 | |
| SCHEMBL147290 | 0.71 | AHR (1.00) | AHRPIK3CDRHEBHTR6MAPK1 | |
| SCHEMBL10718362 | 0.71 | AHR (0.56) | AHRPIK3CDRHEBHTR6MAPK1 | |
| SCHEMBL9232128 | 0.71 | AHR (0.56) | AHRPIK3CDRHEBHTR6MAPK1 | |
| SCHEMBL18805064 | 0.71 | AHR (0.56) | AHRPIK3CDRHEBHTR6MAPK1 | |
| SCHEMBL113992 | 0.71 | AHR (0.56) | AHRPIK3CDRHEBHTR6MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394974-B2 | Process for producing optically active chromene oxide compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-03-12 | — | — | US | disclosed |
| US-8173808-B2 | Substituted naphthalenyl-pyrimidine compounds | ARQULE, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-7964623-B2 | Tricyclic benzopyrane compound | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2011-06-21 | — | — | US | disclosed |
| US-20100081808-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE EPOXY COMPOUND | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-04-01 | — | — | US | disclosed |
| US-20100069374-A1 | Tricyclic benzopyrane compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-7652008-B2 | 2,2,7,9-tetramethyl-4-[(2-phenylethyl)amino]-3,4-dihydro-2H-pyrano[2,3-g]quinolin-3-ol; 3-hydroxy-2,2,9-trimethyl-4-[(2-phenylethyl)amino]-3,4-dihydro-2H-pyrano[2,3-g]quinolin-7-carbonitrile; have the prolongation effect on refractory period | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| EP-2133343-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE EPOXY COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2009-12-16 | — | — | EP | disclosed |
| EP-2003135-A9 | PROCESS FOR PRODUCING OPTICALLY ACTIVE CHROMENE OXIDE COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2009-04-22 | — | — | EP | disclosed |
| US-20090043100-A1 | Process for Producing Optically Active Chromene Oxide Compound | NISSAN CHEMICAL INDUSTRIES, LTD (JP) | 2009-02-12 | — | — | US | disclosed |
| EP-2003135-A2 | PROCESS FOR PRODUCING OPTICALLY ACTIVE CHROMENE OXIDE COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2008-12-17 | — | — | EP | disclosed |
| US-20040038856-A1 | Treatment of fibroproliferative disorders using TGF-beta inhibitors | SCIOS, INC. | 2004-02-26 | — | — | US | disclosed |
| WO-2004010929-A2 | METHODS FOR IMPROVEMENT OF LUNG FUNCTION USING TGF-β INHIBITORS | SCIOS, INC. (US) | 2004-02-05 | — | — | WO | disclosed |
| WO-2003097615-A1 | TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-β INHIBITORS | SCIOS, INC. (US) | 2003-11-27 | — | — | WO | disclosed |
| US-20030069248-A1 | Quinazoline derivatives as medicaments | CHAKRAVARTY SARVAJIT (US) | 2003-04-10 | — | — | US | disclosed |
| US-6476031-B1 | Quinazoline derivatives as medicaments | SCIOS, INC. | 2002-11-05 | — | — | US | disclosed |
| US-20020161010-A1 | Quinazoline derivatives as medicaments | CHAKRAVARTY SARVAJIT (US) | 2002-10-31 | — | — | US | disclosed |
| US-6277989-B1 | USEFUL IN TREATING CONDITIONS THAT ARE CHARACTERIZED BY ENHANCED P38 KINASE ACTIVITY AND/OR TRANSFORMING GROWTH FACTOR BETA (TGF-.BETA.) ACTIVITY SUCH AS INFLAMMATION, PROLIFERATIVE DISEASES, AND CERTAIN CARDIOVASCULAR DISORDERS | SCIOS, INC. | 2001-08-21 | — | — | US | disclosed |
| EP-1107959-A2 | QUINAZOLINE DERIVATIVES AS MEDICAMENTS | SCIOS INC. (US) | 2001-06-20 | — | — | EP | disclosed |
| US-6184226-B1 | ANTIINFLAMMATORY AGENTS FOR TREATMENT OF CARDIOVASCULAR SYSTEM DISORDERS/RESPIRATORY SYSTEM DISORDERS, ANTIISCHEMIC AGENTS | SCIOS INC. | 2001-02-06 | — | — | US | disclosed |
| WO-2000012497-A2 | QUINAZOLINE DERIVATIVES AS MEDICAMENTS | SCIOS INC. (US) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069374-A1 | Tricyclic benzopyrane compound | CBR1, CBR3, CYP2C9 | AHR 644/4885PIK3CD 4331/4885RHEB 4648/4885 |
| US-20100081808-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE EPOXY COMPOUND | OSTC, EEF1D, SQLE | AHR 3375/4885PIK3CD 1403/4885RHEB 546/4885 |
| US-20020161010-A1 | Quinazoline derivatives as medicaments | SMAD3, SMAD2, TGFBR1 | AHR 1725/4885PIK3CD 641/4885RHEB 1894/4885 |
| US-20040038856-A1 | Treatment of fibroproliferative disorders using TGF-beta inhibitors | TGFBR1, TGFBR2, SMAD3 | AHR 4011/4885PIK3CD 2785/4885RHEB 1166/4885 |
| US-20030069248-A1 | Quinazoline derivatives as medicaments | SMAD3, SMAD2, TGFBR1 | AHR 1725/4885PIK3CD 641/4885RHEB 1894/4885 |
| US-20090043100-A1 | Process for Producing Optically Active Chromene Oxide Compound | CYP2C19, CYP2C9, CYP1A2 | AHR 316/4885PIK3CD 1740/4885RHEB 2635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.